CCR2 and neoplasm: In clinical applications, the combination of the oral CCR2 small molecule antagonist PF-04136309 with conventional chemotherapy resulted in partial tumor responses (49%) and local tumor control in 97% of patients with advanced pancreatic ductal adenocarcinoma (PDAC) [125].